Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 6296 entries
Sorted by: Best Match Show Resources per page
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.

The oncologist

Piver MS.
PMID: 10388011
Oncologist. 1996;1(5):326-330.

If instead of the title "Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer," the title were "Drug X Reducing the U.S. Death Rate from Epithelial Ovarian Cancer," there would be great media and medical attention worldwide...

Cite
Piver MS. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Oncologist. 1996;1(5):326-330
Piver, M. S. (1996). Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. The oncologist, 1(5), 326-330.
Piver. "Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate." The oncologist vol. 1,5 (1996): 326-330.
Piver MS. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Oncologist. 1996;1(5):326-330. PMID: 10388011.
Copy Download .nbib Format: NLM
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

The Lancet. Oncology

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH.
PMID: 34895479
Lancet Oncol. 2021 Dec 09; doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09.

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and...

Cite
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021;doi: 10.1016/S1470-2045(21)00470-8.
Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., Bartelt, J. M., Beishuizen, A., Boudjemaa, S., Cepelova, M., Claviez, A., Daw, S., Dieckmann, K., Fernández-Teijeiro, A., Fosså, A., Gattenlöhner, S., Georgi, T., Hjalgrim, L. L., Hraskova, A., Karlén, J., Kluge, R., Kurch, L., Leblanc, T., Mann, G., Montravers, F., Pears, J., Pelz, T., Rajić, V., Ramsay, A. D., Stoevesandt, D., Uyttebroeck, A., Vordermark, D., Körholz, D., Hasenclever, D., & Wallace, W. H. (2021). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz, Christine, et al. "Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial." The Lancet. Oncology vol. (2021). doi: https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021 Dec 09; doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09. PMID: 34895479.
Copy Download .nbib Format: NLM
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

The Lancet. Oncology

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH.
PMID: 34895479
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09.

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and...

Cite
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021;23(1):125-137doi: 10.1016/S1470-2045(21)00470-8.
Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., Bartelt, J. M., Beishuizen, A., Boudjemaa, S., Cepelova, M., Claviez, A., Daw, S., Dieckmann, K., Fernández-Teijeiro, A., Fosså, A., Gattenlöhner, S., Georgi, T., Hjalgrim, L. L., Hraskova, A., Karlén, J., Kluge, R., Kurch, L., Leblanc, T., Mann, G., Montravers, F., Pears, J., Pelz, T., Rajić, V., Ramsay, A. D., Stoevesandt, D., Uyttebroeck, A., Vordermark, D., Körholz, D., Hasenclever, D., & Wallace, W. H. (2022). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, 23(1), 125-137. https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz, Christine, et al. "Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial." The Lancet. Oncology vol. 23,1 (2022): 125-137. doi: https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09. PMID: 34895479; PMCID: PMC8716340.
Copy Download .nbib Format: NLM
Brentuximab Vedotin Infusion Reaction Management: A Case Study.

Journal of the advanced practitioner in oncology

Comer H, Cardwell K.
PMID: 30310723
J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01.

We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest...

Cite
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017;8(6):626-629
Comer, H., & Cardwell, K. (2017). Brentuximab Vedotin Infusion Reaction Management: A Case Study. Journal of the advanced practitioner in oncology, 8(6), 626-629.
Comer, Holly, and Cardwell, Kimbra. "Brentuximab Vedotin Infusion Reaction Management: A Case Study." Journal of the advanced practitioner in oncology vol. 8,6 (2017): 626-629.
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01. PMID: 30310723; PMCID: PMC6167082.
Copy Download .nbib Format: NLM
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

The Lancet. Oncology

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH.
PMID: 34895479
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09.

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and...

Cite
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021;23(1):125-137doi: 10.1016/S1470-2045(21)00470-8.
Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., Bartelt, J. M., Beishuizen, A., Boudjemaa, S., Cepelova, M., Claviez, A., Daw, S., Dieckmann, K., Fernández-Teijeiro, A., Fosså, A., Gattenlöhner, S., Georgi, T., Hjalgrim, L. L., Hraskova, A., Karlén, J., Kluge, R., Kurch, L., Leblanc, T., Mann, G., Montravers, F., Pears, J., Pelz, T., Rajić, V., Ramsay, A. D., Stoevesandt, D., Uyttebroeck, A., Vordermark, D., Körholz, D., Hasenclever, D., & Wallace, W. H. (2022). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, 23(1), 125-137. https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz, Christine, et al. "Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial." The Lancet. Oncology vol. 23,1 (2022): 125-137. doi: https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09. PMID: 34895479.
Copy Download .nbib Format: NLM
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

The Lancet. Oncology

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH.
PMID: 34895479
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09.

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and...

Cite
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021;23(1):125-137doi: 10.1016/S1470-2045(21)00470-8.
Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., Bartelt, J. M., Beishuizen, A., Boudjemaa, S., Cepelova, M., Claviez, A., Daw, S., Dieckmann, K., Fernández-Teijeiro, A., Fosså, A., Gattenlöhner, S., Georgi, T., Hjalgrim, L. L., Hraskova, A., Karlén, J., Kluge, R., Kurch, L., Leblanc, T., Mann, G., Montravers, F., Pears, J., Pelz, T., Rajić, V., Ramsay, A. D., Stoevesandt, D., Uyttebroeck, A., Vordermark, D., Körholz, D., Hasenclever, D., & Wallace, W. H. (2022). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, 23(1), 125-137. https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz, Christine, et al. "Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial." The Lancet. Oncology vol. 23,1 (2022): 125-137. doi: https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09. PMID: 34895479.
Copy Download .nbib Format: NLM
Docetaxel: a new active agent in the therapy of metastatic breast cancer.

Expert opinion on investigational drugs

Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Ten Bokkel Huinink WW.
PMID: 15989586
Expert Opin Investig Drugs. 1997 Dec;6(12):1853-65. doi: 10.1517/13543784.6.12.1853.

Breast cancer is the most common malignancy in women, accounting for about 18% of female cancers, and over half a million new cases are diagnosed worldwide each year. Its incidence increases with age and is currently rising. Although the...

Cite
Fumoleau P, Seidman AD, Trudeau ME, et al. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs. 1997;6(12):1853-65doi: 10.1517/13543784.6.12.1853.
Fumoleau, P., Seidman, A. D., Trudeau, M. E., Chevallier, B., & Ten Bokkel Huinink, W. W. (1997). Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert opinion on investigational drugs, 6(12), 1853-65. https://doi.org/10.1517/13543784.6.12.1853
Fumoleau, P, et al. "Docetaxel: a new active agent in the therapy of metastatic breast cancer." Expert opinion on investigational drugs vol. 6,12 (1997): 1853-65. doi: https://doi.org/10.1517/13543784.6.12.1853
Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Ten Bokkel Huinink WW. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs. 1997 Dec;6(12):1853-65. doi: 10.1517/13543784.6.12.1853. PMID: 15989586.
Copy Download .nbib Format: NLM
Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.

Pleura and peritoneum

Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC.
PMID: 31198851
Pleura Peritoneum. 2019 Mar 26;4(1):20180111. doi: 10.1515/pp-2018-0111. eCollection 2019 Mar 01.

BACKGROUND: Despite optimal surgery and appropriate first-line chemotherapy, ∼70-80 % of patients with epithelial ovarian cancer will develop disease relapse. The prognosis is poor especially for women with Platinum resistant ovarian cancer. The standard treatment for these groups of...

Cite
Somashekhar SP, Ashwin KR, Rauthan A, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial. Pleura Peritoneum. 2019;4(1):20180111doi: 10.1515/pp-2018-0111.
Somashekhar, S. P., Ashwin, K. R., Rauthan, A., & Rohit, K. C. (2019). Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial. Pleura and peritoneum, 4(1), 20180111. https://doi.org/10.1515/pp-2018-0111
Somashekhar, S P, et al. "Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial." Pleura and peritoneum vol. 4,1 (2019): 20180111. doi: https://doi.org/10.1515/pp-2018-0111
Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial. Pleura Peritoneum. 2019 Mar 26;4(1):20180111. doi: 10.1515/pp-2018-0111. eCollection 2019 Mar 01. PMID: 31198851; PMCID: PMC6545874.
Copy Download .nbib Format: NLM
Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking.

Journal of ethnopharmacology

Che YH, Xu ZR, Ni LL, Dong XX, Yang ZZ, Yang ZB.
PMID: 34808299
J Ethnopharmacol. 2022 Mar 01;285:114851. doi: 10.1016/j.jep.2021.114851. Epub 2021 Nov 19.

ETHNOPHARMACOLOGICAL RELEVANCE: Cybister chinensis Motschulsky belongs to the family Dytiscidae. As a traditional Chinese medicine, the insect is called Longshi in the folk and is commonly used to treat enuresis in children and frequent urination in the elderly.AIM OF...

Cite
Che YH, Xu ZR, Ni LL, et al. Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. J Ethnopharmacol. 2021;285:114851doi: 10.1016/j.jep.2021.114851.
Che, Y. H., Xu, Z. R., Ni, L. L., Dong, X. X., Yang, Z. Z., & Yang, Z. B. (2022). Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. Journal of ethnopharmacology, 285114851. https://doi.org/10.1016/j.jep.2021.114851
Che, Yi-Hao, et al. "Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking." Journal of ethnopharmacology vol. 285 (2022): 114851. doi: https://doi.org/10.1016/j.jep.2021.114851
Che YH, Xu ZR, Ni LL, Dong XX, Yang ZZ, Yang ZB. Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. J Ethnopharmacol. 2022 Mar 01;285:114851. doi: 10.1016/j.jep.2021.114851. Epub 2021 Nov 19. PMID: 34808299.
Copy Download .nbib Format: NLM
Recurrent Leiomyosarcoma With Malignant Transformation.

Cureus

Malaviarachchi S, Balawardana J, Senanayake A, Perera R, Liyanage S.
PMID: 33604210
Cureus. 2021 Jan 13;13(1):e12672. doi: 10.7759/cureus.12672.

The soft tissues are comprised of various structures and supportive tissues in the body, including muscle, connective tissues, endothelium, synovium, fat, lymphatics, and fascia. Soft tissue sarcomas may arise in any part of the body. The most common sites...

Cite
Malaviarachchi S, Balawardana J, Senanayake A, et al. Recurrent Leiomyosarcoma With Malignant Transformation. Cureus. 2021;13(1):e12672doi: 10.7759/cureus.12672.
Malaviarachchi, S., Balawardana, J., Senanayake, A., Perera, R., & Liyanage, S. (2021). Recurrent Leiomyosarcoma With Malignant Transformation. Cureus, 13(1), e12672. https://doi.org/10.7759/cureus.12672
Malaviarachchi, Sachini, et al. "Recurrent Leiomyosarcoma With Malignant Transformation." Cureus vol. 13,1 (2021): e12672. doi: https://doi.org/10.7759/cureus.12672
Malaviarachchi S, Balawardana J, Senanayake A, Perera R, Liyanage S. Recurrent Leiomyosarcoma With Malignant Transformation. Cureus. 2021 Jan 13;13(1):e12672. doi: 10.7759/cureus.12672. PMID: 33604210; PMCID: PMC7880827.
Copy Download .nbib Format: NLM
Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma.

Current therapeutic research, clinical and experimental

Lin F, Juan Y, Zheng SE, Shen Z, Tang LN, Zhao H, Yao Y.
PMID: 24683226
Curr Ther Res Clin Exp. 2009 Apr;70(2):150-60. doi: 10.1016/j.curtheres.2009.04.005.

BACKGROUND: Cancer that originates in the bone, termed primary bone cancer, is rare. Osteosarcoma (OS) occurs primarily in growing bone tissue and is more prevalent in children and adolescents. OS in adults is rare, with 3 to 5 cases...

Cite
Lin F, Juan Y, Zheng SE, et al. Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma. Curr Ther Res Clin Exp. 2009;70(2):150-60doi: 10.1016/j.curtheres.2009.04.005.
Lin, F., Juan, Y., Zheng, S. E., Shen, Z., Tang, L. N., Zhao, H., & Yao, Y. (2009). Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma. Current therapeutic research, clinical and experimental, 70(2), 150-60. https://doi.org/10.1016/j.curtheres.2009.04.005
Lin, Feng, et al. "Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma." Current therapeutic research, clinical and experimental vol. 70,2 (2009): 150-60. doi: https://doi.org/10.1016/j.curtheres.2009.04.005
Lin F, Juan Y, Zheng SE, Shen Z, Tang LN, Zhao H, Yao Y. Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma. Curr Ther Res Clin Exp. 2009 Apr;70(2):150-60. doi: 10.1016/j.curtheres.2009.04.005. PMID: 24683226; PMCID: PMC3967322.
Copy Download .nbib Format: NLM
Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking.

Journal of ethnopharmacology

Che YH, Xu ZR, Ni LL, Dong XX, Yang ZZ, Yang ZB.
PMID: 34808299
J Ethnopharmacol. 2021 Nov 19;114851. doi: 10.1016/j.jep.2021.114851. Epub 2021 Nov 19.

ETHNOPHARMACOLOGICAL RELEVANCE: Cybister chinensis Motschulsky belongs to the family Dytiscidae. As a traditional Chinese medicine, the insect is called Longshi in the folk and is commonly used to treat enuresis in children and frequent urination in the elderly.AIM OF...

Cite
Che YH, Xu ZR, Ni LL, et al. Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. J Ethnopharmacol. 2021;114851doi: 10.1016/j.jep.2021.114851.
Che, Y. H., Xu, Z. R., Ni, L. L., Dong, X. X., Yang, Z. Z., & Yang, Z. B. (2021). Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. Journal of ethnopharmacology, 114851. https://doi.org/10.1016/j.jep.2021.114851
Che, Yi-Hao, et al. "Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking." Journal of ethnopharmacology vol. (2021): 114851. doi: https://doi.org/10.1016/j.jep.2021.114851
Che YH, Xu ZR, Ni LL, Dong XX, Yang ZZ, Yang ZB. Isolation and identification of the components in Cybister chinensis Motschulsky against inflammation and their mechanisms of action based on network pharmacology and molecular docking. J Ethnopharmacol. 2021 Nov 19;114851. doi: 10.1016/j.jep.2021.114851. Epub 2021 Nov 19. PMID: 34808299.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 6296 entries